Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Guigao Lin, Kuo Zhang, Jinming Li
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI AG 2015-11-01
Seri Bilgileri:International Journal of Molecular Sciences
Konular:
CRISPR/Cas9
HBV
cccDNA
antiviral
Online Erişim:http://www.mdpi.com/1422-0067/16/11/25950
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller